Poland · Delayed Price · Currency is PLN BioMaxima Statistics
Total Valuation
BioMaxima has a market cap or net worth of PLN 41.60 million. The enterprise value is 53.77 million.
| Market Cap | 41.60M |
| Enterprise Value | 53.77M |
Important Dates
The last earnings date was Wednesday, September 30, 2026.
| Earnings Date | Sep 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioMaxima has 4.19 million shares outstanding. The number of shares has decreased by -1.60% in one year.
| Current Share Class | 4.19M |
| Shares Outstanding | 4.19M |
| Shares Change (YoY) | -1.60% |
| Shares Change (QoQ) | -6.41% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.77M |
Valuation Ratios
The trailing PE ratio is 52.37.
| PE Ratio | 52.37 |
| Forward PE | n/a |
| PS Ratio | 0.68 |
| PB Ratio | 0.87 |
| P/TBV Ratio | 0.88 |
| P/FCF Ratio | 33.54 |
| P/OCF Ratio | 20.84 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.48, with an EV/FCF ratio of 43.28.
| EV / Earnings | 66.88 |
| EV / Sales | 0.88 |
| EV / EBITDA | 9.48 |
| EV / EBIT | 27.79 |
| EV / FCF | 43.28 |
Financial Position
The company has a current ratio of 1.52, with a Debt / Equity ratio of 0.28.
| Current Ratio | 1.52 |
| Quick Ratio | 0.77 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 2.34 |
| Debt / FCF | 10.70 |
| Interest Coverage | 1.72 |
Financial Efficiency
Return on equity (ROE) is 1.69% and return on invested capital (ROIC) is 2.59%.
| Return on Equity (ROE) | 1.69% |
| Return on Assets (ROA) | 1.54% |
| Return on Invested Capital (ROIC) | 2.59% |
| Return on Capital Employed (ROCE) | 3.20% |
| Weighted Average Cost of Capital (WACC) | 6.08% |
| Revenue Per Employee | 431,804 |
| Profits Per Employee | 5,657 |
| Employee Count | 143 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 2.23 |
Taxes
In the past 12 months, BioMaxima has paid 172,000 in taxes.
| Income Tax | 172,000 |
| Effective Tax Rate | 17.53% |
Stock Price Statistics
The stock price has decreased by -21.57% in the last 52 weeks. The beta is 0.28, so BioMaxima's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | -21.57% |
| 50-Day Moving Average | 10.09 |
| 200-Day Moving Average | 10.99 |
| Relative Strength Index (RSI) | 47.00 |
| Average Volume (20 Days) | 2,560 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioMaxima had revenue of PLN 61.75 million and earned 809,000 in profits. Earnings per share was 0.19.
| Revenue | 61.75M |
| Gross Profit | 30.40M |
| Operating Income | 1.95M |
| Pretax Income | 981,000 |
| Net Income | 809,000 |
| EBITDA | 4.97M |
| EBIT | 1.95M |
| Earnings Per Share (EPS) | 0.19 |
Balance Sheet
The company has 1.20 million in cash and 13.37 million in debt, with a net cash position of -12.17 million or -2.90 per share.
| Cash & Cash Equivalents | 1.20M |
| Total Debt | 13.37M |
| Net Cash | -12.17M |
| Net Cash Per Share | -2.90 |
| Equity (Book Value) | 48.33M |
| Book Value Per Share | 12.31 |
| Working Capital | 9.77M |
Cash Flow
In the last 12 months, operating cash flow was 2.01 million and capital expenditures -762,000, giving a free cash flow of 1.25 million.
| Operating Cash Flow | 2.01M |
| Capital Expenditures | -762,000 |
| Depreciation & Amortization | 3.02M |
| Net Borrowing | -3.27M |
| Free Cash Flow | 1.25M |
| FCF Per Share | 0.30 |
Margins
Gross margin is 49.23%, with operating and profit margins of 3.15% and 1.31%.
| Gross Margin | 49.23% |
| Operating Margin | 3.15% |
| Pretax Margin | 1.59% |
| Profit Margin | 1.31% |
| EBITDA Margin | 8.05% |
| EBIT Margin | 3.15% |
| FCF Margin | 2.02% |
Dividends & Yields
BioMaxima does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.60% |
| Shareholder Yield | 1.60% |
| Earnings Yield | 1.93% |
| FCF Yield | 2.98% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |